drugset / Trial / NCT01635127

Efficacy Study of Canakinumab to Treat Urticaria

NCT01635127

Phase 2 Unknown 20 enrolled University of Zurich
RandomizedCrossoverQuadruple-blindTreatment

Summary

Evaluation whether canakinumab leads to improvement of urticaria

Timeline

Start
2012-06
Primary completion
2016-12
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Canakinumab Monoclonal antibody 150 mg Subcutaneous